S&P 500   4,217.92 (-1.64%)
DOW   32,928.69 (-1.51%)
QQQ   354.22 (-1.95%)
AAPL   171.79 (-1.13%)
MSFT   312.18 (-2.99%)
META   301.04 (-1.88%)
GOOGL   132.30 (-1.39%)
AMZN   124.60 (-3.75%)
TSLA   247.97 (-1.44%)
NVDA   435.31 (-2.79%)
NIO   8.67 (-1.37%)
BABA   84.37 (-2.50%)
AMD   100.08 (-3.09%)
T   14.72 (+0.34%)
F   12.05 (-2.11%)
MU   67.89 (-0.10%)
CGC   0.69 (-6.87%)
GE   107.34 (-1.33%)
DIS   79.57 (-2.57%)
AMC   8.08 (-0.86%)
PFE   33.88 (-0.18%)
PYPL   57.46 (-1.88%)
NFLX   375.25 (-1.34%)
S&P 500   4,217.92 (-1.64%)
DOW   32,928.69 (-1.51%)
QQQ   354.22 (-1.95%)
AAPL   171.79 (-1.13%)
MSFT   312.18 (-2.99%)
META   301.04 (-1.88%)
GOOGL   132.30 (-1.39%)
AMZN   124.60 (-3.75%)
TSLA   247.97 (-1.44%)
NVDA   435.31 (-2.79%)
NIO   8.67 (-1.37%)
BABA   84.37 (-2.50%)
AMD   100.08 (-3.09%)
T   14.72 (+0.34%)
F   12.05 (-2.11%)
MU   67.89 (-0.10%)
CGC   0.69 (-6.87%)
GE   107.34 (-1.33%)
DIS   79.57 (-2.57%)
AMC   8.08 (-0.86%)
PFE   33.88 (-0.18%)
PYPL   57.46 (-1.88%)
NFLX   375.25 (-1.34%)
S&P 500   4,217.92 (-1.64%)
DOW   32,928.69 (-1.51%)
QQQ   354.22 (-1.95%)
AAPL   171.79 (-1.13%)
MSFT   312.18 (-2.99%)
META   301.04 (-1.88%)
GOOGL   132.30 (-1.39%)
AMZN   124.60 (-3.75%)
TSLA   247.97 (-1.44%)
NVDA   435.31 (-2.79%)
NIO   8.67 (-1.37%)
BABA   84.37 (-2.50%)
AMD   100.08 (-3.09%)
T   14.72 (+0.34%)
F   12.05 (-2.11%)
MU   67.89 (-0.10%)
CGC   0.69 (-6.87%)
GE   107.34 (-1.33%)
DIS   79.57 (-2.57%)
AMC   8.08 (-0.86%)
PFE   33.88 (-0.18%)
PYPL   57.46 (-1.88%)
NFLX   375.25 (-1.34%)
S&P 500   4,217.92 (-1.64%)
DOW   32,928.69 (-1.51%)
QQQ   354.22 (-1.95%)
AAPL   171.79 (-1.13%)
MSFT   312.18 (-2.99%)
META   301.04 (-1.88%)
GOOGL   132.30 (-1.39%)
AMZN   124.60 (-3.75%)
TSLA   247.97 (-1.44%)
NVDA   435.31 (-2.79%)
NIO   8.67 (-1.37%)
BABA   84.37 (-2.50%)
AMD   100.08 (-3.09%)
T   14.72 (+0.34%)
F   12.05 (-2.11%)
MU   67.89 (-0.10%)
CGC   0.69 (-6.87%)
GE   107.34 (-1.33%)
DIS   79.57 (-2.57%)
AMC   8.08 (-0.86%)
PFE   33.88 (-0.18%)
PYPL   57.46 (-1.88%)
NFLX   375.25 (-1.34%)
NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Price Target & Analyst Ratings

$0.40
+0.01 (+1.27%)
(As of 01:57 PM ET)
Compare
Today's Range
$0.37
▼
$0.41
50-Day Range
$0.38
▼
$0.48
52-Week Range
$0.37
▼
$12.58
Volume
20,979 shs
Average Volume
975,835 shs
Market Capitalization
$4.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Bellerophon Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$2.00
401.25% Upside
High Prediction$2.00
Average Prediction$2.00
Low Prediction$2.00
TypeCurrent
10/3/22 to 10/3/23		1 Month Ago
9/3/22 to 9/3/23		3 Months Ago
7/5/22 to 7/5/23		1 Year Ago
10/3/21 to 10/3/22
Consensus Rating
Hold
Hold
Hold
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$2.00$2.00$2.00$19.00
Predicted Upside401.25% Upside-63.61% Downside-63.61% Downside718.97% Upside
Get Bellerophon Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.


BLPH Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BLPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bellerophon Therapeutics Stock vs. The Competition

TypeBellerophon TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.66
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside405.05% Upside842.51% Upside698.28% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/6/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$30.00 ➝ $2.00+112.09%
6/5/2023Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating		K. Dolliver
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeBuy ➝ Hold
6/5/2023Laidlaw
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Hold
(Data available from 10/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BLPH Price Target - Frequently Asked Questions

What is Bellerophon Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Bellerophon Therapeutics stock is Hold based on the current 2 hold ratings and 1 buy rating for BLPH. The average twelve-month price prediction for Bellerophon Therapeutics is $2.00 with a high price target of $2.00 and a low price target of $2.00. Learn more on BLPH's analyst rating history.

Do Wall Street analysts like Bellerophon Therapeutics more than its competitors?

Analysts like Bellerophon Therapeutics less than other Medical companies. The consensus rating for Bellerophon Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how BLPH compares to other companies.

Does Bellerophon Therapeutics's stock price have much downside?

According to analysts, Bellerophon Therapeutics's stock has a predicted downside of -63.61% based on their 12-month price targets.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:BLPH) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -